440 related articles for article (PubMed ID: 10953355)
1. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
Bouterfa HL; Sattelmeyer V; Czub S; Vordermark D; Roosen K; Tonn JC
Anticancer Res; 2000; 20(4):2761-71. PubMed ID: 10953355
[TBL] [Abstract][Full Text] [Related]
2. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
Cuthbert JA; Lipsky PE
Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells.
Song CY; Kim BC; Lee HS
Transl Res; 2008 Jan; 151(1):27-35. PubMed ID: 18061125
[TBL] [Abstract][Full Text] [Related]
4. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
5. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Joki T; Heese O; Nikas DC; Bello L; Zhang J; Kraeft SK; Seyfried NT; Abe T; Chen LB; Carroll RS; Black PM
Cancer Res; 2000 Sep; 60(17):4926-31. PubMed ID: 10987308
[TBL] [Abstract][Full Text] [Related]
6. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
Swamy MV; Cooma I; Reddy BS; Rao CV
Int J Oncol; 2002 Apr; 20(4):753-9. PubMed ID: 11894121
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Moriceau G; Roelofs AJ; Brion R; Redini F; Ebetion FH; Rogers MJ; Heymann D
Cancer; 2012 Feb; 118(3):750-60. PubMed ID: 21751201
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPases.
Maddala RL; Reddy VN; Rao PV
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2610-5. PubMed ID: 11581207
[TBL] [Abstract][Full Text] [Related]
9. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
10. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
Agarwal B; Bhendwal S; Halmos B; Moss SF; Ramey WG; Holt PR
Clin Cancer Res; 1999 Aug; 5(8):2223-9. PubMed ID: 10473109
[TBL] [Abstract][Full Text] [Related]
11. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
Zohrabian VM; Forzani B; Chau Z; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2009 Jan; 29(1):119-23. PubMed ID: 19331140
[TBL] [Abstract][Full Text] [Related]
12. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
13. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Ogunwobi OO; Beales IL
Am J Gastroenterol; 2008 Apr; 103(4):825-37. PubMed ID: 18371146
[TBL] [Abstract][Full Text] [Related]
14. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.
van de Donk NW; Schotte D; Kamphuis MM; van Marion AM; van Kessel B; Bloem AC; Lokhorst HM
Clin Cancer Res; 2003 Nov; 9(15):5735-48. PubMed ID: 14654559
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Dimitroulakos J; Ye LY; Benzaquen M; Moore MJ; Kamel-Reid S; Freedman MH; Yeger H; Penn LZ
Clin Cancer Res; 2001 Jan; 7(1):158-67. PubMed ID: 11205904
[TBL] [Abstract][Full Text] [Related]
16. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells.
Choi JW; Jung SE
J Pharmacol Exp Ther; 1999 Apr; 289(1):572-9. PubMed ID: 10087052
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin induces apoptosis in malignant mesothelioma cells.
Rubins JB; Greatens T; Kratzke RA; Tan AT; Polunovsky VA; Bitterman P
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1616-22. PubMed ID: 9603146
[TBL] [Abstract][Full Text] [Related]
19. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
20. Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
Mattingly RR; Gibbs RA; Menard RE; Reiners JJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):74-81. PubMed ID: 12235235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
